Plasma Pharmacokinetics of Sulfadiazine Administered Twice Daily versus Four Times Daily Are Similar in Human Immunodeficiency Virus-Infected Patients†

AUTOR(ES)

Jordan, M. Kelli

FONTE

American Society for Microbiology

RESUMO

The pharmacokinetics of 2,000 mg of sulfadiazine administered twice daily (BID) versus those of 1,000 mg administered four times a day were compared in eight human immunodeficiency virus-infected patients. No differences in pharmacokinetic parameters were detected between the regimens. These data provide a pharmacokinetic rationale for BID dosing of sulfadiazine for the treatment and suppression of toxoplasmosis.

Documentos Relacionados

• Pharmacokinetics of Dapsone Administered Daily and Weekly in Human Immunodeficiency Virus-Infected Children
• Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients
• Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients.
• Bioavailability of Once- and Twice-Daily Regimens of Didanosine in Human Immunodeficiency Virus-Infected Children
• Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.